Mayo Clinic and Thermo Fisher Scientific are working together to evaluate next-generation sequencing, mass spectrometry and immunology diagnostic tools for multiple applications, including myeloid leukemia and therapeutic drug monitoring panels to deliver access to more precise and personalized insights for patient care.
Over the years, I have gained extensive experience with academic cancer center External Advisory Boards, including hosting multiple EAB meetings at my own cancer center, chairing the EABs of nine other NCI designated cancer centers, and serving on many others.
